- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02929147
Comparison of Efficacy and Safety of the Postoperative Analgesia Methods
Comparison of Efficacy and Safety of the Postoperative Analgesia Methods for Supratentorial Craniotomy by Integrated Pulmonary Index (IPI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An optimal analgesic therapy is very important for postoperative recovery. In recent years, several studies showed that the prevalence of the moderate to severe pain after craniotomy ranged from 69 to 87% of patients. In a previous study, the investigators showed that the use of morphine based patient controlled analgesia prevented moderate to severe postoperative pain in patients undergoing supratentorial craniotomy. Morphine related side effects such as sedation, miosis, respiratory depression, nausea and vomiting produce a general reluctance for their use in neurosurgery. Therefore, all patients were closely observed to detect opioid related side effects in the intensive care unit for 24 hours following surgery in the previous study. The Integrated Pulmonary Index (IPI) is a new tool that calculates respiratory and hemodynamic parameters noninvasively. In the present study the investigators will use different doses of morphine based PCA and the IPI system to determine more effective and safer morphine dose for postoperative analgesia following supratentorial craniotomy.
90 patients will randomize in 3 groups following supratentorial craniotomy. All patients will previously instruct on the PCA pumps (Abbott Provider, Chicago, USA) and visual analogue scale (VAS) from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. All patients will use PCA for 24 hours following supratentorial craniotomy. In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 3 the PCA will contain placebo. The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
All patients will observe by the Integrated Pulmonary Index (IPI). It is a new device that provides to recognise in a patients respiratory status. This software tool is a single index value ranging from 1 to 10 based on 4 physiological parameters: end tidal carbon dioxide, respiratory rate, oxygen saturation, pulse rate. Patients will asses at 10th minute, 1, 2, 6, 12, and 24 hours postoperatively. Sedation will evaluate according to Ramsay score. VAS scores, total morphine consumption, Ramsay score, blood pressure, heart rate and respiratory rate, the IPI score will record at each time pain will evaluate. Postoperative side effects, including rash, pruritus, nausea and vomiting will record at the same intervals and defined by a scale with 0 = absent or 1 = present. Moreover the lowest IPI score, the apnea count (longer than 30 seconds) and the count of the desaturation events will record in the postoperative 24 hours.
The 3 Groups will compare with respect to VAS scores, morphine consumption, IPI scores, the apnea count, the desaturation events and morphine related side effects during the 24 hours following supratentorial craniotomy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ozlem Korkmaz Dilmen, MD
- Phone Number: +902124143435
- Email: korkmazdilmen@gmail.com
Study Contact Backup
- Name: Yusuf Tunali, MD
- Phone Number: 21876 +902124143000
- Email: ytunali@yahoo.com
Study Locations
-
-
-
Istanbul, Turkey, 34098
- Ozlem Korkmaz Dilmen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of supratentorial neoplasms
Exclusion Criteria:
- Neurological disorders hindering the communication, aphasia, Glasgow Coma Score (GCS) less than 15, drug or alcohol addiction, chronic pain, raised intracranial pressure, allergies to any of the drugs used in this study, hepatic or renal dysfunction, peptic ulcer disease, dementia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Morphine 1 mg
In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
|
In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
|
Experimental: Morphine 0.5
In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
|
In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
|
Active Comparator: Dexketoprofen & Placebo
The Group 3 will take 50 mg dexketoprofen in the recovery room.
Intra venous injections of dexketoprofen will repeat every 8 hours.
|
The Group 3 will take 50 mg dexketoprofen in the recovery room.
Intra venous injections of dexketoprofen will repeat every 8 hours.
Other Names:
In the Group 3 the PCA will contain placebo.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Integrated Pulmonary Index (IPI)
Time Frame: Change from Beseline IPI values in postoperative first 24 hours.(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Change from Beseline IPI values in postoperative first 24 hours.(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain intensity measured by Visual Analog Score
Time Frame: Change from Beseline Pain Intensity in postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Change from Beseline Pain Intensity in postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Sedation level measured by Ramsay score
Time Frame: Change from Beseline Sedation Level in postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Change from Beseline Sedation Level in postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Cumulative Morphine consumption
Time Frame: Change from Baseline in 1postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Change from Baseline in 1postoperative first 24 hours(at 10th minute, 1, 2, 6, 12, and 24 hours post dose)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ozlem Korkmaz Dilmen, MD, Istanbul University - Cerrahpasa (IUC)
Publications and helpful links
General Publications
- Gottschalk A, Berkow LC, Stevens RD, Mirski M, Thompson RE, White ED, Weingart JD, Long DM, Yaster M. Prospective evaluation of pain and analgesic use following major elective intracranial surgery. J Neurosurg. 2007 Feb;106(2):210-6. doi: 10.3171/jns.2007.106.2.210.
- Garah J, Adiv OE, Rosen I, Shaoul R. The value of Integrated Pulmonary Index (IPI) monitoring during endoscopies in children. J Clin Monit Comput. 2015 Dec;29(6):773-8. doi: 10.1007/s10877-015-9665-z. Epub 2015 Feb 11.
- Dilmen OK, Akcil EF, Tunali Y, Karabulut ES, Bahar M, Altindas F, Vehid H, Yentur E. Postoperative analgesia for supratentorial craniotomy. Clin Neurol Neurosurg. 2016 Jul;146:90-5. doi: 10.1016/j.clineuro.2016.04.026. Epub 2016 May 4.
- Akcil EF, Korkmaz Dilmen O, Ertem Vehid H, Yentur E, Tunali Y. The role of "Integrated Pulmonary Index" monitoring during morphine-based intravenous patient-controlled analgesia administration following supratentorial craniotomies: a prospective, randomized, double-blind controlled study. Curr Med Res Opin. 2018 Nov;34(11):2009-2014. doi: 10.1080/03007995.2018.1501352. Epub 2018 Aug 5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Supratentorial Neoplasms
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Analgesics, Opioid
- Narcotics
- Morphine
- Dexketoprofen trometamol
Other Study ID Numbers
- Istanbul U
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Supratentorial Neoplasms
-
Beijing Tiantan HospitalCompleted
-
Beijing Tiantan HospitalChinese PLA General Hospital; The Second Hospital of Hebei Medical University; Beijing Sanbo Brain Hospital and other collaboratorsCompletedAnesthesia, Brain Tumor, Supratentorial,OutcomeChina
-
DyAnsys, Inc.CompletedSupratentorial Brain TumorsIndia
-
National Institute of Mental Health and Neuro Sciences...CompletedSupratentorial Brain Tumor
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingCraniotomy | Quality of Recovery | Postoperative Analgesia | Scalp Nerve Block | Supratentorial TumorChina
-
Cairo UniversityMohamed, Ahmed A., M.D.; Tarek Ahmed Radwan; Mohamed Farid Mohamed; Hamed Fathy...CompletedLMA Versus Mgso4 in Attenuating Stress Response During Emergence of Supratentorial Tumours PatientsEgypt
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMedulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise SpecifiedUnited States, Canada, Australia, Puerto Rico
-
Huashan HospitalCompleted
-
China Medical University, ChinaUnknownBrain Neoplasms | SurgeryChina
Clinical Trials on Morphine
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Javelin PharmaceuticalsCompleted
-
Javelin PharmaceuticalsCompletedPain, PostoperativeUnited States
-
University of MonastirCompletedTitrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings (TIMORNEB)Acute Pain | Post-Traumatic HeadacheTunisia
-
Mahidol UniversityCompletedLung Diseases | Solitary MassThailand
-
University of Colorado, DenverCompletedScoliosis | Pain Management | Spinal FusionUnited States
-
Javelin PharmaceuticalsCompletedPost-Operative Pain | Third Molar Extraction
-
Cukurova UniversityCompleted
-
University College Hospital GalwayCompletedPain, Postoperative | Arthroplasty, Replacement, Knee
-
Rijnstate HospitalCompletedTotal Hip Replacement